COMMUNIQUÉS West-GlobeNewswire

Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
22/06/2026
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which [...]
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
22/06/2026
LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing- [...]
Novel Key Terms For Managing CIDP Published in Neurology® Journal
22/06/2026
CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- The GBS|CIDP Foundation International is thrilled to announce the publication of shared key terms to describe the management of Chronic Inflammatory Demyelinating [...]
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
22/06/2026
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug [...]
INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
22/06/2026
23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet Growth reflects both organic clinic initiatives and acquisition contribution from Family [...]
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
22/06/2026
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizures (p=0.015), with [...]
GuideAI Health Receives FDA 510(k) Clearance for VascularAssist Occlusion Triage
22/06/2026
AI-Powered Triage Software Helps Radiologists Identify and Prioritize Peripheral Vascular Disease in Lower-Extremity CT Imaging BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- GuideAI Health Corp. (" GuideAI " or the " [...]
Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors
22/06/2026
– Series B proceeds will fund clinical proof-of-biology studies of SARM1 inhibitors – First patient dosed in Phase 1b/2a ALS study with NB-4746, an oral, brain-penetrant SARM1 inhibitor – Dosing initiated in a first-in- [...]
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
22/06/2026
RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on June 10, 2026 [...]
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
22/06/2026
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
22/06/2026
COPENHAGEN, Denmark, June 22, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Oxford BioTherapeutics' Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3
22/06/2026
First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development Obrixtamig reaches late-stage development [...]
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
22/06/2026
Sanofi a ppoints Paulo Fontoura as Global Head of R&D Paris , June 22 , 2026 . Sanofi today announced the appointment of Paulo F o ntoura , MD, PhD, FAAN, as Executi v e Vice President, Global Head of Research [...]
CARBIOS présente les résultats de son Assemblée Générale du 18 juin 2026
22/06/2026
Clermont-Ferrand (France), le 22 juin 2026 (7h45 CEST). CARBIOS, (Euronext Growth Paris : ALCRB) annonce les résultats de son Assemblée Générale Ordinaire Annuelle et Extraordinaire du 18 juin 2026. Les actionnaires [...]
CARBIOS presents the results of its Annual General Meeting of June 18, 2026
22/06/2026
Clermont-Ferrand (France), June 22, 2026 (7:45 am CEST). CARBIOS , (Euronext Growth Paris: ALCRB), announces the results of its Annual Ordinary and Extraordinary General Meeting held on June 18, 2026. Shareholders [...]
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
22/06/2026
Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment options DAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as a DLL3 biomarker- [...]
Communiqué de presse : Sanofi nomme Paulo Fontoura à la tête de sa R&D
22/06/2026
Sanofi nomme Paulo Fontoura à la tête de sa R&D Paris , 22 juin 2026. Sanofi annonce la nomination du Dr Paulo Fontoura au poste de Vice-Président Exécutif, Responsable mondial de la Recherche & Développement [...]
SKG Brings Deep Recovery Technology to Father’s Day Gifting
22/06/2026
NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- This Father’s Day, SKG is bringing smart recovery to the top of the gift list with wearable smart massagers designed for dads’ everyday routines. As thoughtful gift options, [...]
Clariane has launched a proposed offering of €333 million of undated deeply subordinated hybrid notes to refinance its ODIRNANE
22/06/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]

Pages